Program
idelalisib
Also written as “Idelalisib”, “CAL-101” and “CAL101”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Idiopathic Pulmonary Fibrosis · Primary Myelofibrosis · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.
Drug pageIdelalisib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 260 open or running | phase 4since Apr 12, 2016 | Jul 1, 2008 | none ahead |
| Calluna Pharma AS | 11 open or running | phase 2since Dec 16, 2024 | Dec 16, 2024 | Nov 2026phase 2 · NCT06736990 |
| Eli Lillyits history only | 11 open or running | phase 4since Oct 16, 2025 | Oct 16, 2025 | May 2030phase 4 · NCT07218341 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Calluna Pharma AS only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2024First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT06736990 · 150 enrolled · United States, Denmark, France and more
Ahead
- Nov 2026Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT06736990
TargetBeta
“An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) ”NCIt, by rule
“PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| duvelisibrule | SecuraBio | phase 3 | 26 |
| leniolisibrule | Pharming Group | phase 3 | 9 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| roginolisibrule | ionctura | phase 2 | 4 |
Studies
The one study Calluna Pharma AS leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06736990Idiopathic Pulmonary Fibrosis · United States, Denmark, France and more | 2 | Active, not recruiting | Nov 2026 | 150 |
How it is read
Names in the registry
- “Idelalisib”, 24 entries
- “CAL-101”, 2 entries
- “CAL101”, 1 entry
- “GS-1101”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 15 studies
- Lymphoma, Follicular, 6 studies
- Idiopathic Pulmonary Fibrosis, 1 study
- Primary Myelofibrosis, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.